high-riskclinic/follow-up,1313–1314
homemonitoring,1311–1312,1313f–1314f
nutritionalmanagement,1312–1313
pulseoximetryfor,1307,1308f
rationalefor,1307,1308f
somaticgrowthfor,1307–1308
stageIIpalliation
progressionthrough,1314–1315
timingof,1314–1315,1315f
weightfor,1307–1308
Interventionalcatheterization,forpulmonarystenosis,789–795
adverseeventsof,797
historicalperspectiveof,789
indicationsfor,789–790,790b
standardtechniquefor,790–794,791f–794f
Interventionaltechniques,253–280
ofacutecardiorenalsyndrome,1422–1425,1424t–1425t
anticoagulationfor,255
balloondilationand,255–256
cathetersandguidewiresfor,255
complicationsof,279–280
extracardiacinterventionswith,268–275
forarterialandvenousobstructions,269–275
shuntsand,268–269
historicalbackgroundof,253
hybridproceduresin,276–279,276f
combinedprocedures,278–279,278f–279f
hypoplasticleftheartsyndrome,276–277,277f
noveltreatmentsin,276–278
pulmonaryvalvereplacement,278
ventricularseptalclosure,277–278,277f–278f
interventionsonsurgicalandothernaturallyoccurringabnormalpathways,275–276,275f–276f
surgicalshuntsandconduits,stentingof,275–276
intracardiacinterventionswith,257–268
onintactatrialseptum,266–268
paravalvarleaksand,268,268f
shuntsand,263–266
valvarheartdisease,257–263
postproceduralconsiderationsfor,279–280
preproceduralnursingconsiderationsfor,254
preproceduralplanningfor,254
principlesof,253–255
proceduresfor,255–257
septaldefects,closureof,257
stentangioplastyand,256
vascularaccessfor,254–255
vascularocclusionand,257
Intima,1355
Intima-mediathickness,measurementof,1370,1370f
Intraaorticballoonpumpingcounterpulsation,foracutecirculatoryfailure,
1187–1188
Intra-atrialleftsuperiorcavalvein,469
Intraatrialreentranttachycardias,inFontancirculation,1327–1328,1327f–1328f
Intraatrialreentrytachycardia,356
Intracardiacinterventions,withinterventionaltechniques,257–268
Intra/extracardiacFontan,1301,1302f
Intrahepaticportosystemicshunt,471
Intraoperativeechocardiography,incardiopulmonarybypass,233
Intrapericardialarterialtrunks,945
Intrapericardialoutflowtracts,anatomyof,945,946f
Intrauterinedeviceswithcongenitalheartdisease,1442
Intrauterinegrowthretardation,definitionof,190b
Intravenousimmunoglobulin,forKawasakisyndrome,989,992
Intravenousprostacyclinanalogues,forpulmonaryhypertension,1389
Intubation,withprostaglandins,forprematurity,210–211
Invasiveelectrophysiologicstudy,358–359
procedureof,358–359
anesthesiain,358–359
cathetersin,359,360f
Ironoverloading,arterialdysfunctionand,1374
Irritability,inKawasakisyndrome,992
Isomericatrialappendages,visceralsymmetrywithout,452
Isomerism,8–9,8f
ofatrialappendages,441–456
anatomy,442–449
atrial,442–443,442f–444f
ofatrialseptum,447
ofatrioventricularjunctions,447–449,448f
cardiacpositionand,449
ofconductiontissues,449
thoracoabdominalorganarrangementand,451–452,451f
ofvenoatrialconnections,443–447,445f–448f
visceralsymmetrywithoutisomericatrialappendages,452
J
Jamesprotocol,388,389f
JapanCongenitalCardiovascularSurgicalDatabase,1511t–1514t
JapaneseRegistryforPatientswithMechanicalCirculatorySupport,1511t–
1514t
“Job-lock”phenomenon,1463
Junctionalectopictachycardia,348–349,348f
Juvenilehyperthyroidism,cardiacinvolvementin,1096
Juvenilehypothyroidism,cardiacinvolvementin,1096
Juvenileidiopathicarthritis,cardiacinvolvementin,1109
Juvenilespinalmuscularatrophy,cardiacinvolvementin,1106
K
Kabukisyndrome,1415–1416,1415f,1415t
Kallidin,incontrolofcirculation,1358